Related Experiment Video
Updated: Aug 16, 2025
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Towards Personalized Management of Ovarian Cancer
Mashael Algethami1, Sanat Kulkarni2, Maaz T Sadiq3
1Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham, NG7 3RD, UK.
Abstract:
Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60-80%, most patients will have recurrence and succumb to the disease. However, a DNA repair-directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.
Insights
DNA repair-targeted therapies, including PARP inhibitors, offer new hope for advanced ovarian cancer patients. These precision medicine strategies are improving survival for those with BRCA mutations and platinum-sensitive disease.
Area of Science:
- Oncology
- Genetics
- Precision Medicine
Background:
- Advanced ovarian cancer outcomes remain poor despite surgery and chemotherapy.
- Most patients experience recurrence after initial platinum-based chemotherapy response.
Purpose of the Study:
- To review the clinical status of PARP inhibitors and other targeted therapies for ovarian cancer.
- To highlight advancements in DNA repair-directed precision medicine.
Main Methods:
- Review of current clinical data on PARP inhibitors.
- Analysis of other targeted treatment approaches in ovarian cancer.
Main Results:
- PARP inhibitors have significantly improved outcomes for BRCA-deficient and platinum-sensitive ovarian cancer patients.
- Antiangiogenic agents, intraperitoneal chemotherapy, and immunotherapy show promise.
Conclusions:
- DNA repair-directed precision medicine, particularly PARP inhibitors, represents a major advance in ovarian cancer treatment.
- Emerging targeted therapies and immunotherapies offer further potential to improve patient survival.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...